126 related articles for article (PubMed ID: 36575944)
1. Editorial Comment on "Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors".
Izumi M
Pathol Int; 2023 Jan; 73(1):37-38. PubMed ID: 36575944
[No Abstract] [Full Text] [Related]
2. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
3. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.
Kim YJ; Jung CJ; Na H; Lee WJ; Chang SE; Lee MW; Park CS; Lim Y; Won CH
Diagn Pathol; 2022 Apr; 17(1):41. PubMed ID: 35484605
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
6. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
7. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
8. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
9. Correlation of FISH and PRAME Immunohistochemistry in Ambiguous Superficial Cutaneous Melanocytic Proliferations.
Harvey NT; Peverall J; Acott N; Mesbah Ardakani N; Leecy TN; Iacobelli J; McCallum D; Van Vliet C; Wood BA
Am J Dermatopathol; 2021 Dec; 43(12):913-920. PubMed ID: 33899766
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
11. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
12. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions.
Olds H; Utz S; Abrams J; Terrano D; Mehregan D
J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798
[TBL] [Abstract][Full Text] [Related]
13. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.
Roy SF; Panse G; McNiff JM
J Cutan Pathol; 2023 May; 50(5):450-454. PubMed ID: 36789669
[TBL] [Abstract][Full Text] [Related]
14. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
Schmitt TA; Lee JC; Martinka M; Ko KYC
J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
[TBL] [Abstract][Full Text] [Related]
15. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
16. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study.
O'Connor MK; Dai H; Fraga GR
J Cutan Pathol; 2022 Sep; 49(9):780-786. PubMed ID: 35672262
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
18. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
[TBL] [Abstract][Full Text] [Related]
19. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
20. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]